What are the effects of abruptly stopping vemurafenib/zobovo after taking it for 5 days?

Vemurafenib/zobovo(Vemurafenib) is an oral BRAF V600 mutation-selective inhibitor, mainly used to treat advanced melanoma and some solid tumors with BRAF V600E or V600K mutations. Its mechanism of action is to inhibit the mutant BRAF kinase, block the MAPK/ERK signaling pathway, inhibit the proliferation of tumor cells and induce apoptosis. In clinical applications, vemurafenib usually needs to be taken continuously to maintain drug concentration in the body and ensure efficacy.

If a patient suddenly stops taking vemurafenib for only 5 days, a series of effects may occur. First, the drug has not yet reached steady-state blood concentration, and short-term use often fails to fully inhibit tumor signaling pathways. After drug withdrawal, tumor proliferation signals may rapidly recover and the risk of disease progression increases. Especially for patients with advanced melanoma, reactivation of the MAPK pathway may lead to accelerated tumor growth, thereby missing the best window for early control.

Secondly, discontinuation of vemurafenib may also affect the management of side effects. The drug may cause side effects such as rash, joint pain or mild fatigue during short-term use. If the drug is stopped suddenly, although the symptoms may be relieved, the patient's tolerance assessment and safety monitoring of the drug will not be completed, which is detrimental to the subsequent restart of treatment or the formulation of a combination drug regimen. In addition, some patients may develop psychological anxiety after stopping the drug and worry about the loss of efficacy, thus affecting overall treatment compliance.

It is worth emphasizing that vemurafenib should be discontinued under the guidance of a professional doctor, and a gradual reduction or adjustment plan should be developed according to the patient's specific conditions. For clinicians, assessing tumor burden, genetic mutation status, and the patient's overall health are key factors in deciding whether to discontinue treatment or adjust dosage. If a patient must interrupt treatment, for example because of a serious adverse reaction, it is usually recommended to resume treatment as soon as their condition permits to avoid reduced efficacy or rapid disease progression.

Reference: https://www.drugs.com/mtm/vemurafenib.html